Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.02 | -0.04 | -0.05 |
| FCF Yield | 0.00% | -147.21% | -270.50% | -53.83% |
| EV / EBITDA | 0.00 | -0.64 | 0.05 | -0.90 |
| Quality | ||||
| ROIC | 0.00% | -61.23% | -434.09% | -39.39% |
| Gross Margin | 93.55% | 32.35% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.80 | 0.68 | 1.00 | 1.61 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 42.77% | -4.06% | 3.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.77 | 0.31 | 1.08 |
| Interest Coverage | 0.00 | -100.68 | -207.40 | -103.49 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -5,215.49 | -1,204.50 | -1,587.51 |